The main goal of treating carotid artery disease is to prevent a future stroke. Today, our product portfolio consists of the following four single use components. The primary endpoint was the combined outcome of perioperative stroke and/or death. We also provide training through physician proctors on an as needed basis. Most Class II devices are subject to premarket review and clearance by the FDA. Clinical data is sometimes required to support substantial equivalence. If it is not, the agency will refuse to file the PMA. The FDA and CDPH have broad post-market and regulatory enforcement powers. Conformity assessments for our products are carried out as required by the MDD. Requirements of these laws and penalties for violations vary widely. Applicable manufacturers are required to submit annual reports to CMS. These include: ▪Courage: We think big. We challenge ourselves and our colleagues to try new things that are difficult. We explore new ideas and do things differently. During 2020, the number of employees increased by 57. We practice paying competitive salaries and hourly wages. We continue to review and may seek other available benefits under CARES Act. The ultimate impact of COVID-19 is highly uncertain and subject to change. Fluctuations in quarterly and annual results may decrease the value of our common stock. We plan to dedicate significant resources to our marketing programs. As a result, we bear the risk of potential warranty claims on our products. If a court agrees, we would lose our rights to those challenged patents. We may be unable to obtain necessary licenses on satisfactory terms, if at all.